Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Renal Cell × exemestane × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2 NET 1 Gastrointestinal 1 Endocrine 1 Breast 1

Conditions

Tuberous Sclerosis 1 Neuroendocrine Tumors 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1

Interventions

Everolimus 2 regorafenib 1 exemestane 1 entrectinib 1 cabozantinib 1 Nivolumab 1 LY2584702 1 Injections 1 Erlotinib Hydrochloride 1 Clinical Trials, Phase II as Topic 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

SAPU NANO (US) LLC

Phase 1 Recruiting

EndocrineGastrointestinalGenitourinaryNET

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡